Epiomed Therapeutics Obtains Series A Round

  • Feed Type
  • Date
  • Company Name
    Epiomed Therapeutics
  • Mailing Address
    25 Mauchly Irvine, CA 92618
  • Company Description
    The company is developing novel, small molecule anti-emetic and anti-motion sickness compounds.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds from this financing are anticipated to be used for development of Epiomed’s lead anti-emetic compound, designated “ETI-0001” with a Phase 1/2 clinical assessment of ETI-0001 anticipated starting in 1Q 2012.
  • M&A Terms
  • Venture Investor

Trending on Xconomy